Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Inclusion Criteria:

• Male or female ≥18 years of age

• Treated with eculizumab for PNH for at least 3 months prior to Day 1

• LDH level ≤1.5 × upper limit of normal (ULN) at screening

• PNH diagnosis confirmed by documented high-sensitivity flow cytometry.

• Documented meningococcal vaccination not more than 3 years prior to, or at the timeof, initiating study treatment.

• Body weight ≥40 to <100 kilogram (kg)

• Female participants of childbearing potential must use highly effectivecontraception starting at screening and continuing until at least 8 months after thelast dose of ravulizumab.

• Willing and able to give written informed consent and comply with study visitschedule.

Exclusion Criteria:

• More than 1 LDH value > 2 × ULN within the 3 months prior to study entry

• History of bone marrow transplantation.

• History of or ongoing major cardiac, pulmonary, renal, endocrine, or hepatic diseasethat, in the opinion of the Investigator or Sponsor, would preclude participation.

• Unstable medical conditions (for example, myocardial ischemia, activegastrointestinal bleed, severe congestive heart failure, anticipated need for majorsurgery within 6 months of randomization, coexisting chronic anemia unrelated toPNH).

• Females who are pregnant, breastfeeding or who have a positive pregnancy test atscreening or Day 1.

• Participation in another interventional clinical study or use of any experimentaltherapy within 30 days before initiation of study drug on Day 1 in this study orwithin 5 half-lives of that investigational product, whichever is greater.